Six more Michigan companies in industries ranging from bicycles to off-grid power to high-tech health have received investments from the Michigan Pre-Seed Capital Fund, totaling $1.5 million.
Comcast, Michigan’s No. 1 cable TV provider, Tuesday announced the Michigan launch of Xfinity Home Control, a new product under the Xfinity Home umbrella of services.
The Concours d’Elegance kicks off Sunday in Plymouth — where beautiful, classic and exotic automobiles will be on display.
Burroughs Inc. Thursday announced a software distributor agreement with Sullivan, Ill.-based Jaguar Software Development Inc. to sell and distribute its MirrorImage suite of application modules which can be configured to handle different item processing environments in the financial industry.
Esperion Therapeutics Inc. (Nasdaq: ESPR), the Plymouth-based developer of new drugs to lower cholesterol levels in the blood, announced that the underwriters of its recently completed initial public offering have exercised in full their option to purchase an additional 750,000 shares of common stock from Esperion to cover over-allotments.
PLYMOUTH — For the second time, a Michigan company called Esperion Therapeutics is selling stock to the public. Esperion Wednesday announced a $14-a-share price for an initial public offering of 5 million shares. Esperion is […]
Esperion Therapeutics Inc. Friday announced “positive” results from a Phase 2a clinical study of its product candidate ETC-1002 in patients with high cholesterol and a history of bad reactions to existing statin drugs.
Thirty-two new charter schools that meet “very specific educational needs” are scheduled to open in Michigan this fall.
The Plymouth-based cholesterol drug developer Esperion Therapeutics Inc. has filed for an initial public stock offering with the federal Securities and Exchange Commission. Esperion is seeking to raise up to $70 million.
Esperion Therapeutics’ proposed new cholesterol-busting drug cut the level of low-density lipoprotein, the so-called bad choleterol, up to 43 percent in a Phase 2 test of diabetic patients.